BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34067658)

  • 1. The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma.
    Martija AA; Pusch S
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMP3 as a prognostic biomarker correlates with EMT in GBM.
    Li L; Xia S; Zhao Z; Deng L; Wang H; Yang D; Hu Y; Ji J; Huang D; Xin T
    BMC Cancer; 2024 Jan; 24(1):89. PubMed ID: 38229014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.
    Jun F; Hong J; Liu Q; Guo Y; Liao Y; Huang J; Wen S; Shen L
    Oncotarget; 2017 Feb; 8(9):14343-14358. PubMed ID: 27527869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
    Oh S; Yeom J; Cho HJ; Kim JH; Yoon SJ; Kim H; Sa JK; Ju S; Lee H; Oh MJ; Lee W; Kwon Y; Li H; Choi S; Han JH; Chang JH; Choi E; Kim J; Her NG; Kim SH; Kang SG; Paek E; Nam DH; Lee C; Kim HS
    Nat Commun; 2020 Jul; 11(1):3288. PubMed ID: 32620753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial Membrane Protein-3 and Chitinase-3-like Protein-1 as New Prognostic Predictors of Glioma, a Two-Gene Study.
    Shen K; Zhu J; Zhou S; Jin X; Zhai W; Sun L; Wu J; Yu Z
    Curr Oncol; 2023 Sep; 30(10):8686-8702. PubMed ID: 37887529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma.
    Martija AA; Krauß A; Bächle N; Doth L; Christians A; Krunic D; Schneider M; Helm D; Will R; Hartmann C; Herold-Mende C; von Deimling A; Pusch S
    Acta Neuropathol Commun; 2023 Nov; 11(1):177. PubMed ID: 37936247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.
    Pasini A; Iorio P; Bianchi E; Cerasoli S; Cremonini AM; Faedi M; Guarnieri C; Guiducci G; Riccioni L; Molinari C; Rengucci C; Calistri D; Giordano E
    Oncol Rep; 2012 Dec; 28(6):2271-7. PubMed ID: 22992787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High EMP3 expression might independently predict poor overall survival in glioblastoma and its expression is related to DNA methylation.
    Yue H; Xu Q; Xie S
    Medicine (Baltimore); 2018 Jan; 97(1):e9538. PubMed ID: 29505529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a nomogram with EMP3 for predicting clinical outcomes in patients with glioma: A bi-center study.
    Zhang A; Xu H; Zhang Z; Liu Y; Han X; Yuan L; Ni Y; Gao S; Xu Y; Chen S; Jiang J; Chen Y; Zhang X; Lou M; Zhang J
    CNS Neurosci Ther; 2021 Oct; 27(10):1238-1250. PubMed ID: 34268874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
    J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of STAT3 gene expression in patients with glioblastoma tumors: a study from Western India.
    Trivedi T; Panchal K; Bhalala N; Trivedi P
    J Egypt Natl Canc Inst; 2022 Jul; 34(1):30. PubMed ID: 35844028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.
    Alaminos M; Dávalos V; Ropero S; Setién F; Paz MF; Herranz M; Fraga MF; Mora J; Cheung NK; Gerald WL; Esteller M
    Cancer Res; 2005 Apr; 65(7):2565-71. PubMed ID: 15805250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.